Genenta Science SpA ADR Asset Resilience Ratio
Genenta Science SpA ADR asset resilience ratio. Genenta Science SpA ADR (GNTA) has an Asset Resilience Ratio of 70.94% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Genenta Science SpA ADR (GNTA) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Genenta Science SpA ADR (2021–2025)
Asset resilience ratio of Genenta Science SpA ADR from 2021 to 2025. This chart shows how Genenta Science SpA ADR's Asset Resilience Ratio has changed over time. Read Genenta Science SpA ADR total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Genenta Science SpA ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Genenta Science SpA ADR (GNTA) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $22.62 Million | 70.94% |
| Total Liquid Assets | $22.62 Million | 70.94% |
Asset Resilience Insights
- Very High Liquidity: Genenta Science SpA ADR maintains exceptional liquid asset reserves at 70.94% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Genenta Science SpA ADR Industry Peers by Asset Resilience Ratio
Compare Genenta Science SpA ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Genenta Science SpA ADR Asset Resilience Ratio by Year (2021–2025)
Genenta Science SpA ADR asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Genenta Science SpA ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 70.94% | $22.62 Million | $31.89 Million | +16.44pp |
| 2024-12-31 | 54.49% | $8.08 Million | $14.82 Million | -13.01pp |
| 2023-12-31 | 67.50% | $15.08 Million | $22.35 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $33.44 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $40.03 Million | -- |
About Genenta Science SpA ADR
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for us… Read more